|

LXP1788 is administered intravenously via Port-A Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • LaunXP Biomedical Co., Ltd.1

Indications

  • Liver Disease1
  • Solid Tumor Malignancies, Cancer1
  • RCC, Renal Cell Cancer1
  • Solid Tumour1
  • Solid Tumors Refractory to Standard Therapy1

Other1 trial

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.